VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours
CHENG VWT. et al, (2018), Clinical Cancer Research
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
Middleton MR., (2018), Lancet Oncol, 19, 1424 - 1426
Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands
LU X. et al, (2018), Nature Communications
A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Corrie PG. et al, (2018), Ann Oncol, 29 Suppl 8
Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors.
Middleton MR. et al, (2018), Ann Oncol, 29 Suppl 8
Systematic review of patient-reported outcome measures used in randomised clinical trials testing checkpoint inhibitor immunotherapy for cancer
Peters M. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S117 - S118
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC. et al, (2018), The Lancet. Oncology, 19, 1027 - 1039
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
Lipplaa A. et al, (2018), British Journal of Cancer
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology
A decision support system for the treatment of esophageal cancer
Mistry H. et al, (2018), CANCER RESEARCH, 78
INCIDENCE AND MANAGEMENT OF IMMUNOTHERAPY-INDUCED COLITIS IN A TERTIARY IBD CENTRE - CLINICAL PRACTICE DATA
Gupta T. et al, (2018), GUT, 67, A186 - A187
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.
Azaro A. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.
Shoushtari AN. et al, (2018), Journal of Clinical Oncology, 36, 9593 - 9593
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP. et al, (2018), Scientific reports, 8, 7265 - 7265
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D. et al, (2018), J Clin Oncol, 36, 1291 - 1299
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
Lee RJ. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology, 29, 490 - 496
Incidence and management of immunotherapy-induced colitis in a tertiary melanoma and IBD centre: Clinical practice data
Cheung V. et al, (2018), JOURNAL OF CROHNS & COLITIS, 12, S198 - S198